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Review Article
Introduction
According to the World Health Organization Cancer Report, 
in 2012 there were 1.4 million new cases and 694 000 deaths 
from colorectal cancer (CRC) worldwide.1 In terms of inci-
dence, CRC is the third most common cancer in men and 
the second in women. CRC is the fourth most common can-
cer in developed regions and the fifth most common cancer 
in less developed regions. Compared with the 2010 study, 
CRC had increased in both incidence rate and mortality.1
Chemotherapy is the primary therapy for CRC in the pal-
liative setting.2 Oxaliplatin combined with 5-fluorouracil 
(5-FU)/leucovorin (LV), referred to as FOLFOX, is stan-
dard first-line chemotherapy in the palliative setting for 
advanced CRC.3 Oxaliplatin combined with oral 
capecitabine, which converts to 5-FU in the body, is referred 
to as XELOX.4 Capecitabine was found to be as effective as 
intravenous 5-FU/LV.5,6
Natural products have been the source of a number of 
cancer drugs and continue to play a role in drug discovery 
programs.7 Traditional medicines (TMs) based on natural 
products are used by a considerable proportion of cancer 
patients, often in combination with conventional 
therapies.8-11 A number of compounds contained in plants 
possess pro-apoptotic actions, which may assist in the pre-
vention or suppression of tumor growth and/or enhance 
cytotoxic effects of chemotherapeutic agents.12-15
In China, chemotherapy may be combined with TMs 
with the aim of reducing the side effects of the chemother-
apy and/or inhibiting tumor growth.16 A meta-analysis of 
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Abstract
This meta-analysis evaluates the clinical evidence for the addition of traditional medicines (TMs) to oxaliplatin-based 
regimens for colorectal cancer (CRC) in terms of tumor response rate (TRR). Eight electronic databases were searched 
for randomized controlled trials of oxaliplatin-based chemotherapy combined with TMs compared to the same oxaliplatin-
based regimen. Data on TRR from 42 randomized controlled trials were analyzed using Review Manager 5.1. Studies were 
conducted in China or Japan. Publication bias was not evident. The meta-analyses suggest that the combination of the TMs 
with oxaliplatin-based regimens increased TRR in the palliative treatment of CRC (risk ratio [RR] 1.31 [1.20-1.42], I2 = 
0%). Benefits were evident for both injection products (RR 1.36 [1.18-1.57], I2 = 0%) and orally administered TMs (RR 1.27 
[1.15-1.41], I2 = 0%). Further sensitivity analysis of specific plant-based TMs found that Paeonia, Curcuma, and Sophora 
produced consistently higher contributions to the RR results. Compounds in each of these TMs have shown growth-
inhibitory effects in CRC cell-line studies. Specific combinations of TMs appeared to produce higher contributions to TRR 
than the TMs individually. Notable among these was the combination of Hedyotis, Astragalus, and Scutellaria.
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TMs combined with FOLFOX4 found that the TMs con-
ferred benefits to advanced CRC patients in terms of tumor 
response rate (TRR), quality of life, and some adverse 
events, when compared to FOLFOX4 alone. In addition, 
this study reported that experimental studies of the TMs 
most frequently used in the clinical trials had shown evi-
dence of bioactivities of relevance to cancer therapy and 
should be considered for further research.17 The interven-
tions included in the review by Chen et al17 were primarily 
of multicomponent TMs. Although it is likely that the fre-
quent TMs in the multicomponent formula were contribu-
tors to the pooled outcomes, it is possible that other lower 
frequency TMs may be of research interest, particularly 
with regard to their effect on TRR, which is the most fre-
quently reported primary outcome in cancer trials.18 In 
addition, one reason for using multi-ingredient TMs is the 
concept of synergetic action, so it is possible that certain 
combinations of TMs may be more effective than these 
TMs individually.19
In this study, we aimed to identify which TMs, and which 
combinations of TMs, were associated with elevated TRRs 
in clinical trials of CRC. We conducted a meta-analysis of 
randomized controlled trials of TMs combined with oxali-
platin regimens for CRC in order to select TMs for further 
clinical and experimental research regarding their effects on 
tumor growth.
Method
Eight databases were searched from their inceptions to 
November 2013: PubMed, EMBASE, Cochrane 
CENTRAL, CINAHL, Science Direct, PsycINFO, China 
Academic Journals (CNKI), and Chinese Science and 
Technology Journals (CQVIP). Search terms were grouped 
as follows: (a) Disorder: colorectal cancer and related 
terms; (b) Intervention: herbal medicine, complementary 
medicine, traditional medicine, and related terms; and (c) 
Study type: controlled trial, randomized and related terms 
(see Supplement 1 for PubMed terms; all supplementary 
materials are available online at http://ict.sagepub.com/con-
tent/by/supplemental-data). Reference lists in reviews and 
clinical studies and additional Chinese language journals 
were hand-searched separately.
Studies included in meta-analyses were randomized con-
trolled trials that employed oxaliplatin regimens combined 
with a TM intervention in the test arm and the same oxali-
platin regimen in the control arm that provided data on 
TRR, regardless of blinding with no restrictions on lan-
guage or publication year. Test interventions were TMs in 
any form, including extracts, by any administration route. 
All participants had been diagnosed based on pathology 
tests with CRC at different stages and all had received pal-
liative treatment. Tumor response criteria were complete 
response (CR), partial response (PR), stable disease (SD), 
and progressive disease (PD). CR plus PR were included in 
data pooling as TRR.20,21
Data extraction and risk of bias assessments were con-
ducted by 2 reviewers independently (MC and IZ) with 
mediation by AZ or BM. Review Manager (RevMan) 5.1 
was used for meta-analysis. Methods were based on 
Cochrane Handbook 5.1.0.22 Risk ratio (RR) with 95% con-
fidence interval (95% CI) using a fixed effect model was 
used unless there was evidence of moderate heterogeneity. 
Proportion of heterogeneity was measured using I2. 
Sensitivity tests were conducted when I2 ≥ 50%. Studies 
with zero events were included to avoid overestimation of 
effect.23 When the same outcome was reported by more 
than 10 studies, publication bias was assessed using a fun-
nel plot.22
Subgroup analyses were planned based on the method of 
administration of the TM. Further sensitivity analyses were 
planned for studies of multi-ingredient orally administered 
TM interventions that contained the same plants. We rea-
soned that if a particular TM plant possessed tumor inhibi-
tory properties, this would be reflected in the pooled TRR 
outcomes of the group of studies that used TM interventions 
containing this plant. In the case of the most frequently used 
plant-based TMs, we expected that the TRRs of the studies 
that included these plants would tend toward the pooled 
result of all studies whereas the less frequently used plants 
would be distributed above and below the result of the total 
pool. Therefore, by investigating the pooled TRRs of groups 
of studies that had plant-based TMs in common, we could 
identify plants that showed potential for further research.
First, analyses were undertaken for each plant-based TM 
that was present in 2 or more TM interventions. Then com-
binations of TMs were assessed as pairs, triplets, and higher 
level combinations to determine which combinations of 
TMs produced greater or lesser changes in TRR. The fol-
lowing multilevel procedure was used:
1. Pooled TRRs were calculated for each group of 
studies that contained the same TM. These were 
listed in descending order and any significant results 
were noted.
2. Pairs of TMs that were present in 2 or more studies 
were identified. The pooled RRs were calculated, 
listed in descending order, and any significant 
results were noted.
3. The same procedure was conducted for groups of 3, 
4, and more TMs as the data set allowed. This pro-
duced a matrix of results for RR, 95% CI, heteroge-
neity, and sample size.
In assessing the TM combinations, only actual combina-
tions were included. For example, although the pairing of 
TM1 with TM2 may appear possible, all the TM interven-
tions that contain TM1 + TM2 may also include TM3. 
 at RMIT University Library on November 21, 2015ict.sagepub.comDownloaded from 
Chen et al 3
Therefore, the RR of this group is actually due to the com-
bination of the 3 TMs and there is no independent contribu-
tion from the pair TM1 + TM2. Therefore, only the group 
TM1 + TM2 + TM3 was included in the RR results matrix.
The following criteria were used to identify promising 
TMs: (a) significantly increased RR relative to controls and 
lack of important heterogeneity (I2 not greater than 30%); 
and (b) consistent RR results at multiple levels of combina-
tion. When combinations of TMs showed RRs higher than 
those of the TMs separately, these were identified as possi-
ble examples of a synergistic effect.
Results
Database searches located 2648 potentially relevant cita-
tions, and 54 additional studies were identified from 
reference lists and print journals. Following screening, 88 
studies were considered and the 42 studies of TM combined 
with oxaliplatin regimen versus the same oxaliplatin regi-
men alone that reported TRR were included in meta-analy-
ses (Figure 1). These 42 studies enrolled 3070 assessable 
participants with 1613 in the test groups and 1457 in the 
controls. All studies were published from 2005 to 2013. 
Forty-one studies were conducted in China and one in 
Japan.24 Participant characteristics, interventions, and out-
come measurements are summarized in Table 1. Thirty-one 
studies used the TMs orally. Eleven studies employed com-
mercially available TM injections. Oxaliplatin regimens 
included the following: 5-FU plus LV combined with oxali-
platin (FOLFOX) in 39 studies, or the combination of oxali-
platin and capecitabine (XELOX) in 3 studies. Dosages and 
schedules are recorded in Table 1.
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Figure 1. Flow diagram of the search and selection process of randomized controlled trials (RCTs) of oxaliplatin regimens combined 
with traditional medicine (TM) for colorectal cancer (CRC).
Abbreviations: CT, clinical trial of TM without randomization; DU, duplicate publication; MT, multi-cancer CT; RE, review; Other, not a controlled 
trial, not an RCT of TM, or outcome is not TRR.
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Methodological Assessment
All studies stated the use of randomization. Fifteen studies 
(35.7%) described a proper method of sequence generation 
(SG), so risk of bias was judged as “low.” Two studies24,25 
described allocation concealment (AC), used blinding of 
participants (BPt) and a placebo control for the TM, so these 
were judged “low risk” for these domains. The other studies 
did not describe procedures for AC, so were judged “unclear 
risk” for AC and “high risk” for BPt since the participants 
would know they were receiving an additional therapy. 
Blinding of outcome assessors (BOA) for TRR was not 
mentioned. Blinding of participants is difficult to achieve in 
cancer trials.18 Since TRR is an objective outcome that is 
measured by radiologists and laboratory pathologists, it was 
unlikely to have been influenced by any lack of blinding so 
this domain was assessed as “low risk” (Table 1).
Four studies reported the numbers of participants who 
dropped out during the trial or were lost to follow-up,26-29 
but reasons were not given and these missing data were not 
treated as “intent to treat.” So these were judged as “high 
risk” of attrition bias. Studies that had the same numbers of 
participants at inception as in the outcome reports were 
judged as “low risk” of incomplete outcome data (IOD). 
Only Kono et al had published a study protocol.24 When the 
objectives and outcome measures stated in the method sec-
tion were all reported in the results section, the study was 
judged as “low risk” of selective outcome reporting (SOR; 
Table 1). The 42 studies showed symmetry for TRR in the 
funnel plot, suggesting the risk of publication bias was low 
(Supplementary Figure 1).
Meta-Analysis of Tumor Response
The World Health Organization solid tumor response crite-
ria were used to evaluate TRR in 35 studies, and 6 studies 
used the RECIST criteria (Table 1). As these use similar 
categories,30 data could be pooled for all studies. Meta-
analyses were conducted for CR and TRR. When RR is 
more than +1 (IV model, fixed, 95% CI), it favors the test 
group. Meta-analyses were performed for the following 
groups: Total (42 studies); Non-oral (injection) group (11 
studies), and Oral administration group (31 studies).
Total Group. In the 42 studies (n = 3070), the test groups 
showed significantly improved TRR (RR 1.31 [1.20-1.42], 
I2 = 0%; Figure 2). CR was significantly higher compared 
to controls (RR 1.80 [1.28-2.51], I2 = 0%). A sensitivity 
analysis of the 15 studies judged low risk of bias for SG 
showed a significant increase in TRR (RR 1.24 [1.07, 
1.42], I2 = 0%).
Non-Oral Group. Ten different injection products were 
tested in 11 studies (n = 938; Table 1). There were signifi-
cant improvements for TRR (RR 1.36 [1.18-1.57], 
I2 = 0%) and CR (RR 1.91 [1.11-3.27], I2 = 0%) compared 
to controls (Figure 2). The TRR funnel plot was symmetric 
(Supplementary Figure 1). When each product was ana-
lyzed separately, Shenqi injection (n = 1)31 showed signifi-
cantly improved TRR compared to control. The others 
showed trends but not significance (Figure 2).
Oral Administration Group. In 31 studies (n = 2145), TMs 
were administered orally as decoctions, capsules, or tablets. 
Two studies by the same author used the same multi-ingre-
dient TM.32,33 The pooled TRR showed significant improve-
ment (RR 1.27 [1.15-1.41], I2 = 0%; Figure 2). CR improved 
significantly (RR 1.61 [1.03-2.52], I2 = 0%).
Effects of Plant-Based Ingredients in the Oral 
Administration Group
The multi-ingredient TM formulae tended to differ in name 
but there was considerable similarity in their main ingredi-
ents (Table 1). In order to identify the most comparable sub-
groups of studies in terms of the TM interventions used and 
to select TMs for further research, we undertook a series of 
planned sensitivity analyses based on the presence of the 
same ingredients in the TM interventions.
The effects on TRR of the TM plants used in multiple 
studies are reported at the level of the single TM, pair of 
TMs, and groups of 3 or more TMs. Since the aim was to 
select TMs for further research, only TMs with signifi-
cant RR results for tumor response that were equal or 
greater than the pooled RR are reported in the text. In 
Table 2, all significant RR results (excluding those with 
heterogeneity >30%) are rank-ordered according to 
descending RR.
Level 1: Single TMs. All TM plant ingredients (n = 87) in the 
formulae were recorded in a spreadsheet. The number of 
TMs per formula averaged 12 and ranged from 2 to 25. 
Thirty-one out of 87 TMs were used in 2 or more formulae. 
For TMs, the full botanical names are given in the first 
instance together with the plant part used, the Chinese name 
in pin yin, and plant family. Thereafter, the name is short-
ened to the genus only.
The most frequently used TMs were the following: 
Atractylodes macrocephala Koidz. root [bai zhu] Asteraceae 
(n = 23); Coix lacryma-jobi L. seed [yi ren] Gramineae (n = 
19); Poria cocos (Schw) Wolf sclerotium [fu ling] 
Polyporaceae (n = 19); Astragalus membranaceus (Fisch.) 
Bge. root [huang qi] Fabaceae (n = 18); Codonopsis pilo-
sula (Franch.). Nannf. root [dang shen] Campanulaceae (n 
= 17); Curcuma zedoaria (Berg.) Rosc. or C phaeocaulis 
Val. rhizome [e zhu] Zingiberaceae (n = 11); Hedyotis dif-
fusa Willd. aerial parts [she she cao] Rubiaceae (n = 10); 
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Figure 2. Forest plot of meta-analysis of tumor response rate (TRR) of TM plus oxaliplatin-based regimen versus oxaliplatin-based 
regimen. 
References: Oral group24-29,32,33,73-95; Non-oral group96-105
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Table 2. Effects of Specific Orally Administered Traditional Medicines (TMs) on Tumor Response: Single TMs and Combinations.
Level Traditional Medicine RR 95% CI No. of Studies, References No. Part. I2 %
1 Coptis 1.49 [1.18, 1.89] 373-75 221 29
1 Sanguisorba 1.49 [1.18, 1.89] 373-75 221 29
1 Aucklandia 1.45 [1.16, 1.80] 573,75-78 340 0
1 Paeonia 1.44 [1.18, 1.77] 525,73-75,79 409 0
1 Sophora 1.44 [1.17, 1.77] 525,73-75,77 401 0
1 Akebia 1.41 [1.09, 1.83] 527,73,80-82 310 16
1 Sparganium 1.36 [1.13, 1.64] 625,32,33,73,75,83 491 0
1 Curcuma 1.34 [1.14, 1.58] 1125,29,32,33,73-75,80,82-84 797 0
1 Citrus 1.30 [1.07, 1.59] 628,75,76,82,85,86 420 0
1 Pinellia 1.28 [1.02, 1.59] 728,79,82,85-88 514 0
1 Coix 1.25 [1.08, 1.46] 1926,28,29,74,76-80,82-91 1283 0
1 Hedyotis 1.25 [1.06, 1.49] 1025,28,29,75-77,81-83,88 687 0
1 Astragalus 1.24 [1.08, 1.43] 1824-29,32,33,73-84,88,91,92 1194 0
1 Scutellaria 1.24 [1.04, 1.49] 925,26,74-77,80,82,83 599 0
1 Atractylodes 1.23 [1.08, 1.41] 2325-29,32,33,74,76-86,88,89,91,93 1549 0
1 Poria 1.23 [1.06, 1.43] 1924,26,28,32,33,74,76,78,79,81-89,91 1213 0
1 Codonopsis 1.23 [1.07, 1.41] 1725,26,32,33,75,76,78,81-83,85,86,88,91,93 1206 0
2 Sophora + Aucklandia 1.51 [1.18, 1.92] 373,75,77 221 27
2 Sparganium + Curcuma 1.36 [1.13, 1.64] 625,32,33,73,75,83 491 0
2 Paeonia + Astragalus 1.31 [1.04, 1.65] 425,74,75,79 311 0
2 Codonopsis + Citrus 1.30 [1.07, 1.59] 628,75,76,82,85,86 420 0
2 Astragalus + Hedyotis 1.26 [1.06, 1.51] 925,28,29,75-77,82,83,88 647 0
2 Poria + Coix 1.26 [1.06, 1.49] 1526,28,74,76,78,79,82-89,91 981 0
2 Curcuma + Astragalus 1.25 [1.04, 1.49] 925,29,32,33,74,75,80,82,83 635 0
2 Coix + Atractylodes 1.25 [1.06, 1.47] 1726,28,29,74,76-80,82-86,88,89,91 1105 0
2 Astragalus + Scutellaria 1.24 [1.04, 1.49] 925,26,74-77,80,82,83 599 0
2 Codonopsis + Hedyotis 1.23 [1.03, 1.46] 825,28,75,76,81-83,88 575 0
2 Atractylodes + Hedyotis 1.23 [1.00, 1.51] 925,28,29,76,77,81-83,88 624 0
2 Astragalus + Codonopsis 1.23 [1.05, 1.43] 1325,26,28,32,33,74-76,78,82,83,88,91 902 0
2 Poria + Atractylodes 1.23 [1.05, 1.44] 1726,28,32,33,74,76,78,79,81-86,88,89,91 1105 0
2 Atractylodes + Astragalus 1.23 [1.05, 1.44] 1725-29,32,33,74,76-80,82,83,88,91 1131 0
2 Poria + Codonopsis 1.21 [1.02, 1.43] 1426,28,32,33,74,76,78,81-83,85,86,88,91 923 0
2 Atractylodes + Codonopsis 1.21 [1.04, 1.41] 1625,26,28,32,33,74,76,78,81-83,85,86,88,91,93 1143 0
3 Sophora + Paeonia + Curcuma 1.44 [1.16, 1.78] 425,73-75 341 8
3 Sophora + Astragalus + Scutellaria 1.31 [1.04, 1.65] 425,74,75,77 303 0
3 Curcuma + Astragalus + Hedyotis 1.30 [1.05, 1.60] 525,29,75,82,83 363 0
3 Astragalus + Hedyotis + Scutellaria 1.28 [1.04, 1.56] 625,75-77,82,83 431 0
3 Pinellia + Coix + Poria 1.28 [1.02, 1.59] 728,79,82,85-88 514 0
3 Codonopsis + Scutellaria + Hedyotis 1.26 [1.03, 1.56] 525,75,76,82,83 371 0
3 Astragalus + Codonopsis + 
Scutellaria
1.26 [1.04, 1.53] 725,26,74-76,82,83 469 0
3 Curcuma + Astragalus + Codonopsis 1.25 [1.04, 1.52] 725,32,33,74,75,82,83 513 0
3 Coix + Poria + Atractylodes 1.25 [1.05, 1.49] 1426,28,74,76,78,79,82-86,88,89,91 923 0
3 Curcuma + Astragalus + Scutellaria 1.24 [1.02, 1.51] 625,74,75,80,82,83 441 0
3 Astragalus + Codonopsis + Hedyotis 1.24 [1.03, 1.49] 715,28,75,76,82,83,88 535 0
3 Atractylodes + Astragalus + 
Hedyotis
1.24 [1.00, 1.54] 825,28,29,76,77,82,83,88 584 0
3 Coix + Poria + Astragalus 1.22 [1.01, 1.48] 1326,28,29,74,76-80,82,83,88,91 827 0
3 Poria + Atractylodes + Astragalus 1.21 [1.00, 1.46] 1226,28,32,33,74,76,78,79,82,83,88,91 787 0
3 Poria + Atractylodes + Codonopsis 1.21 [1.02, 1.43] 1426,28,32,33,74,76,78,81-83,85,86,88,91 923 0
3 Atractylodes + Astragalus + 
Codonopsis
1.20 [1.00, 1.44] 1225,26,28,32,33,74,76,78,82,83,88,91 839 0
(continued)
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Level Traditional Medicine RR 95% CI No. of Studies, References No. Part. I2 %
4 Sophora + Paeonia + Sparganium + 
Curcuma
1.45 [1.16, 1.80] 325,73,75 281 38
4 Astragalus + Hedyotis + Aucklandia 
+ Scutellaria
1.31 [1.00, 1.70] 375-77 183 0
4 Sophora + Scutellaria + Hedyotis + 
Astragalus
1.30 [1.02, 1.66] 325,75,77 243 0
4 Astragalus + Codonopsis + Citrus + 
Hedyotis
1.29 [1.01, 1.64] 428,75,76,82 256 0
4 Curcuma + Astragalus + Scutellaria 
+ Codonopsis
1.28 [1.03, 1.57] 525,74,75,82,83 371 0
4 Pinellia + Coix + Atractylodes + 
Poria
1.27 [1.00, 1.60] 628,79,82,85,86,88 456 0
4 Sparganium + Curcuma + Astragalus 
+ Codonopsis
1.25 [1.01, 1.53] 525,32,33,75,83 393 0
4 Coix + Atractylodes + Poria + 
Codonopsis
1.23 [1.02, 1.49 1126,28,74,76,78,82,83,85,86,88,91 741 0
5 Sanguisorba + Coptis + Sophora + 
Paeonia + Curcuma
1.49 [1.18, 1.89] 373-75 221 29
5 Sophora + Scutellaria + Aucklandia + 
Astragalus + Hedyotis
1.33 [1.00, 1.76] 275,77 123 0
5 Codonopsis + Scutellaria + Citrus + 
Hedyotis + Astragalus
1.29 [1.00, 1.65] 375,76,82 183 0
5 Curcuma + Codonopsis + Hedyotis 
+ Scutellaria + Astragalus
1.27 [1.02, 1.58] 425,75,82,83 311 0
6 Sophora + Curcuma + Scutellaria + 
Astragalus + Codonopsis + Paeonia
1.29 [1.02, 1.65] 325,74,75 243 0
6 Sparganium + Curcuma + Hedyotis 
+ Astragalus + Scutellaria + 
Codonopsis
1.27 [1.01, 1.61] 325,75,83 251 0
8 Paeonia + Curcuma + Hedyotis 
+ Sophora + Sparganium + 
Codonopsis + Astragalus + 
Scutellaria
1.29 [1.00, 1.66] 225,75 183 0
Abbreviations: RR, risk ratio for tumor response; 95% CI, 95% confidence interval; No. Part., number of participants; I2%, measure of heterogeneity.
Table 2. (continued)
Scutellaria barbata D. Don. aerial parts [ban zhi lian] 
Labiatae (n = 9); and Pinellia ternata (Thunb.) Breit. tuber 
[ban xia] Araceae (n = 7).
The TRRs of the group of studies that included each par-
ticular TM were calculated. The RRs were sorted from high 
to low, significant RRs were identified (n = 25), and groups 
with moderate heterogeneity (I2 > 30%) were excluded (n = 
8), leaving 17 different TMs in the following analyses 
(Table 2). The pooled RR results were divided into 3 groups: 
(a) RR significant and greater or equal to the RR of the total 
pool (ie, 1.27); (b) RR significant but less than the total 
pool; and (c) not significant (not reported).
The first group, in descending order of RR, included 10 
TMs: Sanguisorba officinalis L. root [di yu] Rosaceae (n = 
3); Coptis chinensis Franch. root [huang lian] Ranunculaceae 
(n = 3); Aucklandia lappa Decne. root [mu xiang] Asteraceae 
(n = 5); Sophora flavescens Ait. root [ku shen] Fabaceae (n = 
5); Paeonia lactiflora Pall. or P veitchii Lynch. root [chi 
shao] Ranunculaceae (n = 5); Akebia quinata (Thunb.) 
Decne. fruit [ba yue zha] Lardizabalaceae (n = 5); 
Sparganium stoloniferum Buch.-Hamil. root [san leng] 
Sparganiaceae (n = 6); Curcuma (n = 11); Citrus reticulata 
Blanco peel [chen pi] Rutaceae (n = 6); and Pinellia (n = 7; 
Table 2).
In the second group, the following 7 TMs showed sig-
nificant RRs that were slightly lower than the RR of the 
pool: Coix, Hedyotis, Astragalus, Scutellaria, Atractylodes, 
Poria, and Codonopsis (Table 2). The frequency of each TM 
was plotted against the RR to explore any relationships. It 
was evident that the higher frequency TMs tended to be 
closer the RR of the pool while the lower frequency TMs 
showed a broader distribution above and below the pool 
(Supplementary Figure 2). Nonsignificant TMs had fre-
quencies of 6 or less and all TMs excluded due to heteroge-
neity had frequencies of 2 or 3. Therefore, all the higher 
frequency TMs remained in the analysis.
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Level 2: Pairs of TMs. TMs (n = 17) that showed significant 
RR results were paired with other TMs from groups 1 or 2 
above. The 4 pairs that showed RRs that were above or 
equal to the total pool, in descending order of RR, were 
the following: Sophora + Aucklandia (n = 3), Sparganium 
+ Curcuma (n = 6), Paeonia + Astragalus (n = 4), and 
Codonopsis + Citrus (n = 6). A further 12 pairs were sig-
nificant but had RRs lower than the total for the pool 
(Table 2).
Level 3: Combinations of 3 TMs. The significant pairs from 
level 2 were combined with other TMs that showed signifi-
cant RRs at level 1. The 5 triplets that showed RR values 
above or equal to the total pool, in descending order of RR, 
were the following: Sophora + Curcuma + Paeonia (n = 4), 
Sophora + Astragalus + Scutellaria (n = 4), Curcuma + 
Astragalus + Hedyotis (n = 5), Pinellia + Poria + Coix (n = 
7), and Astragalus + Hedyotis + Scutellaria (n = 6). An addi-
tional 11 triplets showed significant RRs that were lower 
than the total for the pool (Table 2).
Level 4: Combinations of 4 TMs. The significant combina-
tions from level 3 were combined into groups of four. Six 
combinations showed RRs above or equal to the total pool: 
Sophora + Paeonia + Sparganium + Curcuma (n = 3), 
Astragalus + Hedyotis + Aucklandia + Scutellaria (n = 3), 
Sophora + Scutellaria + Hedyotis + Astragalus (n = 3), 
Astragalus + Codonopsis + Citrus + Hedyotis (n = 4), Cur-
cuma + Astragalus + Scutellaria + Codonopsis (n = 5), and 
Pinellia + Coix + Atractylodes + Poria (n = 6). An addi-
tional 2 combinations showed significant RRs that were 
lower than the pool total (Table 2).
Level 5: Combinations of 5 TMs. The significant combina-
tions from level 4 were combined into groups of five. 
Four combinations showed RRs equal or higher than the 
pool: Sanguisorba + Coptis + Sophora + Paeonia + Cur-
cuma (n = 3), Sophora + Scutellaria + Aucklandia + 
Astragalus + Hedyotis (n = 2), Codonopsis + Scutellaria 
+ Citrus + Hedyotis + Astragalus (n = 3), and Curcuma + 
Codonopsis + Hedyotis + Scutellaria + Astragalus (n = 4; 
Table 2).
Level 6: Combinations of 6 or More TMs. The significant com-
binations from level 5 were further combined. There were 2 
combinations of 6 TMs. One showed an RR higher than the 
pool: Sophora + Curcuma + Scutellaria + Astragalus + 
Codonopsis + Paeonia (n = 3); and the other was equal to 
the pool: Sparganium + Curcuma + Hedyotis + Astragalus + 
Scutellaria + Codonopsis (n = 3). There were no combina-
tions of 7 TMs, and there was one combination of 8 which 
showed an RR equal to the pool: Paeonia + Curcuma + 
Hedyotis + Sophora + Sparganium + Codonopsis + Astrag-
alus + Scutellaria (n = 2; Table 2).
TMs With Consistent Results at Multiple Levels
Combinations of up to 8 TMs produced RR results that 
were equal or higher than the total for the pool. Seven TMs 
appeared at all levels: Astragalus, Codonopsis, Scutellaria, 
Hedyotis, Sophora, Curcuma, and Paeonia. Of these, 
Sophora, Curcuma, and Paeonia showed significant TRR 
results that were equal or higher than the total for the pool 
at each level.
Potential Synergistic Effects of TMs
Three TM pairs showed higher RRs as pairs than for the 
TMs singly: Sophora + Aucklandia, Coix + Poria, and 
Astragalus + Hedyotis (Table 2). Of these, the first pair also 
had an RR higher than the pool.
Three TM triplets showed potential synergistic effects: 
Astragalus + Hedyotis + Scutellaria, Astragalus + 
Codonopsis + Scutellaria, and Codonopsis + Hedyotis + 
Scutellaria. Of these, the RR of the first triplet was also 
higher than the pool.
The combination Sophora + Paeonia + Sparganium + 
Curcuma showed an increased RR as a group, compared to 
the pooled results of the single TMs but there was important 
heterogeneity (I2 = 38%). The group Sanguisorba + Coptis 
+ Sophora + Paeonia + Curcuma had an RR that was equal 
or superior to the single TMs.
Discussion
All 42 included studies employed oxaliplatin regimens in 
the test and control groups. These are currently first-line 
chemotherapy regimens for CRC in the palliative setting, so 
the results of these meta-analyses are of direct clinical rel-
evance. The heterogeneity of meta-analyses was zero for 
the TRR and CR results, and publication bias was not evi-
dent. The pooled data indicate the addition of the TMs sig-
nificantly improved TRR when compared to oxaliplatin 
regimens alone. Benefits were evident in the subgroups for 
injections and orally administered TMs (Figure 2). These 
results were consistent with a previous article that focused 
on FOLFOX-4 and included a number of the same studies.17 
As discussed in that article, blinding is difficult in cancer 
trials and weaknesses in study design may have biased out-
comes in favor of the combined treatment. Regarding the 
question of how the TMs may act, Chen et al17 discussed the 
effects of the 6 TMs that most frequently appeared in the 
formulae: Astragalus, Atractylodes, Poria, Coix, Sophora, 
and Panax ginseng C.A. Mey. In experimental studies, 
these TMs had been reported to possess antiproliferative 
and other properties, which may have accounted for the 
effects reported in the clinical trials.17
In this article, the most frequently used plants were simi-
lar—Atractylodes, Coix, Poria, and Astragalus; however, 
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some TM interventions may not have aimed at improving 
TRR, and may have been focused on improving outcomes 
relating to adverse effects of chemotherapy and/or improv-
ing quality of life. Therefore, some TMs would not be 
expected to make individual contributions to the TRR 
results. To explore the contribution of each individual TM 
to the meta-analysis results for TRR, we used sensitivity 
analyses of the subgroups of studies that contained the same 
plants to investigate whether any particular plants were 
associated with elevated RRs.
With regard to selecting the most promising TMs for fur-
ther research, it was evident that many TMs showed signifi-
cant RRs either singly or in combination with other TMs. 
For example, Coptis and Sanguisorba appeared the most 
promising at level 1 based on their individual RRs (Table 2), 
but these TMs were infrequent overall and did not appear at 
each level so they could not show consistent results at mul-
tiple levels. In contrast, Sophora, Paeonia, and Curcuma all 
appeared at 7 levels of combination with RRs that were sig-
nificant and equal or above the pool at each level, without 
heterogeneity and based on sample sizes of 400 participants 
or more; hence, they showed consistent benefit and were 
selected as promising for further research. Nevertheless, this 
does not mean that Coptis and Sanguisorba and other plants 
with high RRs show no promise. It is notable that there were 
no significant negative RRs for any of the TMs or their com-
binations, which suggests that the TMs were not inhibiting 
the actions of the chemotherapy.
The results suggest synergistic actions for some TM 
combinations. Hedyotis, Astragalus, and Scutellaria all 
appeared frequently in the formulae and each has been 
reported to inhibit CRC in vitro and in vivo.34-36 These TMs 
showed significant RRs but all were slightly lower than the 
pool as singles. However, these TMs showed higher RRs in 
combinations at levels 3 to 6, and all are in the final group 
of 8 TMs. These results suggest that this grouping should 
also be subject to further research to explore potential syn-
ergistic effects between these plants and their compounds 
on tumor response as well as their effects when combined 
with oxaliplatin.
An advantage of this approach to the identification of 
TMs for further research is that it is based on the contribu-
tions of the individual TMs to tumor response rather than on 
their frequency in formulae. This sensitivity analysis proce-
dure allows identification of TM plants that appear at rela-
tively low frequencies within the total data set. Had 
frequency been used as the criterion for selection, 
Atractylodes, Poria, and Astragalus would have been identi-
fied but Sophora, Paeonia, and Curcuma may have been 
missed. Conversely, a limitation to this method for selecting 
TMs and TM combinations is that the data set provides a 
restricted number of actual TM combinations at each level. 
Therefore, all the possible combinations cannot be assessed. 
Also, as the levels increase, the number of significant 
combinations declines and so does the number of studies 
from which the data are derived. Consequently, the proce-
dures used will remove very low frequency TMs from the 
data set.
It should be noted that the RR results cannot provide 
direct comparisons between TMs in terms of efficacy since 
the pooled data are based on multiple studies that used 
multi-ingredient interventions. Consequently, Sophora, 
Paeonia, and Curcuma cannot be considered more effective 
than the other TMs that showed significant RRs. Rather, 
these TMs showed consistent benefits in terms of TRR 
based on multiple clinical studies and multiple combina-
tions. In addition, these 3 TMs have all shown evidence of 
antitumor activity in experimental studies.
Actions of Paeonia (chi shao)
The TM chi shao can be derived from the roots of Paeonia 
lactiflora and Paeonia veitchii, both of which can contain 
paeonol and paeoniflorin.37,38 In human colon cancer LoVo 
cells, paeonol blocked cell cycle at the G1 to S transition and 
induced apoptosis.39 In HT-29 cells, paeonol inhibited 
proliferation40 and showed a synergetic antiproliferative 
effect when combined with 5-FU.41 In human esophageal 
adenocarcinoma cells, paeonol showed a dose-dependent 
growth-inhibitory effect, and this effect was synergistic when 
combined with cisplatin.42 Paeonol appears to influence mul-
tidrug resistance. It showed reversal of resistance in a 
paclitaxel-resistant human breast cancer cell line43 and 
reversed endoplasmic reticulum (ER) stress-induced resis-
tance to doxorubicin in human hepatocellular carcinoma 
cells.44 Paeoniflorin has shown growth-inhibitory, pro-apop-
totic effects in human cervical cancer HeLa cells45 as well as 
anti-inflammatory effects in a colitis model46 and in human 
umbilical vein endothelial cells.47
The combination of extracts of Paeonia and Astragalus 
were found to synergistically induce the expression of leu-
kotriene B4-12-hydroxydehydrogenase (LTB4DH) in a 
dose- and time-dependent manner leading to cell-cycle 
arrest in HepG2 cells by controlling the leukotriene B4 
pathway.48 Although this combination has not been investi-
gated in colon cancer, the leukotriene B4 pathway plays an 
important role in the proliferation of colon cancer cells.49
Actions of Curcuma (e zhu)
The official sources of e zhu are Curcuma wenyujin Y. H. 
Chen et C. Ling, C. phaeocaulis Val., and C. kwangsiensis 
S. G. Lee et C. F. Liang,50 but older sources use the name 
C. zedoaria Roscoe.51 The rhizomes contain multiple aro-
matic compounds including elemenes and nonvolatile com-
pounds such as curcumins.50
Curcumin has been investigated in multiple cancer 
cell-lines.52 In human colon cancer HT-29 and HCT-15 cells it 
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dose-dependently inhibited proliferation53 and induced apop-
tosis in colorectal carcinoma HCT116 cells and human CRC 
LoVo Cells.52,54 A study of curcumin combined with FOLFOX 
in 2 colon cancer cell-lines (HCT-116 and HT-29) reported a 
synergistic growth-inhibitory effect, which appeared to 
involve the EGFR and IGF-1R growth factor pathways.55
Delta-elemene was found to dose- and time-dependently 
induce apoptosis in colorectal adenocarcinoma (DLD-1) 
cells.56 Beta-elemene has shown growth-inhibitory activity 
in multiple cancer cell-lines including CCL-222 and CCL-
225 colon carcinoma cells.57 In colo205 colorectal adeno-
carcinoma cells, it also increased cisplatin cytotoxicity.58 
Beta-elemene exhibits low toxicity in normal cells, having 
much weaker anti-proliferative effects in normal human 
lung fibroblast CCD-19Lu cells, human bronchial epithelial 
NL20 cells, and human ovary epithelial IOSE-397 cells 
compared to the corresponding cancer cell-lines.50
Actions of Sophora (ku shen)
The dried roots of Sophora flavescens Aiton. contain a 
number of alkaloids, including matrine, oxymatrine, sopho-
ridine, and sophocarpine, and flavonoids such as kurarinone.59 
It is traditionally used to treat solid tumors and inflamma-
tory diseases.60 Since 1992, products containing total 
Sophora alkaloids, oxymatrine and matrine, have been 
approved by the Chinese State Food and Drug Administration 
for the treatment of various types of solid tumors.61
In human colon cancer HT 29 cells, Xiao et al reported 
that a range of ethanol and aqueous extracts of Sophora 
roots inhibited cell growth in vitro.62 In a model of cancer 
cachexia, sophocarpine and matrine both reduced cachexia 
symptoms in BALB/c mice inoculated with colon26 adeno-
carcinoma cells and suppressed the expression of the pro-
inflammatory cytokines TNF-a and IL-6.63
Huang et al reported that matrine dose-dependently 
inhibited human colon cancer HT29 cell proliferation by 
promoting apoptosis.64 Chang et al also reported that 
matrine inhibited proliferation of HT29 cells. Matrine 
appeared to activate caspase-3 and caspase-9 and release 
cytochrome-c to induce apoptosis.65 In human colon cancer 
LoVo cells, Zhang et al reported that matrine inhibited pro-
liferation in a time- and dose-dependent manner. They 
found the mechanisms of action of matrine were via induc-
ing cell cycle arrest at the G1 phase by downregulation of 
cyclin D1 and upregulation of p27 and p21. Apoptosis was 
induced by reduction of the Bcl-2/Bax ratio and caspase-9 
activation. Matrine was reported to have an upstream effect 
on these proteins by inactivating Akt.66
In a mouse model using transplanted colon tumor SW480 
cells, sophoridine reduced tumor weight and volume and 
reduced expression of p53 and VEGF.67 In xenografts of 
SW480 cells in mice, Liang et al reported that sophoridine 
inhibited tumor growth with no apparent toxicity, and in an 
SW480 cell-line study its action was via caspase-9, cas-
pase-3, caspase-7, and PARP.68
Matrine and oxymatrine have shown synergistic effects 
with different anticancer agents.69 Matrine showed synergis-
tic effects when combined with celecoxib, trichostatin A, and 
rosiglitazone against proliferation and VEGF expression in 
MDA-MB-231 breast cancer cells70 and enhanced the activ-
ity of trichostatin A in human non–small cell lung cancer 
A549 cells.71 In a transplanted human gastric cancer SGC-
7901 model in nude mice, the inhibitory effect of matrine 
combined with 5-FU was greater than either compound used 
individually, without increasing bone marrow inhibition.72
In a study that compared the antitumor activities of total 
Sophora alkaloids (KS-As) and flavonoids (KS-Fs), Sun 
et al reported higher growth inhibitory effects for KS-Fs, 
and for kurarinone in particular, than for KS-As in multiple 
cancer cell-lines including human CRC CaCo-2 cells. There 
was little effect on the peripheral blood cell numbers in nor-
mal mice treated with KS-Fs. KS-Fs also enhanced the 
cytotoxicity of Taxol and Adriamycin.60
Conclusions
The meta-analyses suggest that the combination of the TMs 
with oxaliplatin-based regimens significantly increased 
TRR in the palliative treatment of CRC. Benefits were evi-
dent for both injection products and orally administered 
TMs. Detailed sensitivity analyses of specific plant-based 
TMs found that Paeonia, Curcuma, and Sophora produced 
consistent contributions to the TRR results. Compounds in 
each of these TMs have shown growth-inhibitory effects in 
CRC cell-lines. There were no instances of TMs reducing 
the TRR of the chemotherapy. Specific combinations of 
TMs appear to produce higher contributions to TRR than 
the TMs individually. Notable among these is the combina-
tion of Hedyotis, Astragalus, and Scutellaria. Further stud-
ies are required to investigate the effects of the TMs 
identified in this study and the possible synergistic effects 
of the TM combinations.
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